Quick Answer
Travere Therapeutics, Inc. reported Research And Development Expense of $140.96 million for the year ending 2019.
- Travere Therapeutics, Inc. showed an increase of +13.9% in Research And Development Expense from 2018 to 2019.
- This data is from Travere Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2020.
- XBRL data for this metric is available from 2012 to 2019 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2012: $110.7 thousand | Q1 2013: $158.7 thousand | Q2 2013: $605.2 thousand | Q3 2013: $1.40 million | Q1 2014: $6.94 million | Q2 2014: $13.31 million | Q3 2014: $12.65 million | Q1 2015: $10.35 million | Q2 2015: $10.56 million | Q3 2015: $14.06 million | Q1 2016: $14.67 million | Q2 2016: $17.68 million | Q3 2016: $18.41 million | Q1 2017: $20.86 million | Q2 2017: $19.48 million | Q3 2017: $19.61 million | Q1 2018: $24.64 million | Q2 2018: $34.46 million | Q3 2018: $32.45 million | Q1 2019: $33.44 million | Q2 2019: $37.93 million | Q3 2019: $33.22 million | Q1 2020: $30.25 million | Q2 2020: $30.79 million | Q3 2020: $32.35 million | Q1 2021: $47.95 million | Q2 2021: $51.81 million | Q3 2021: $48.41 million.
- Over the full 8 years of available data (2012 to 2019), Travere Therapeutics, Inc.'s Research And Development Expense has grown by 21,177.4%.
- Historical annual values: Fiscal year 2019: $140.96 million | Fiscal year 2018: $123.76 million | Fiscal year 2017: $78.17 million | Fiscal year 2016: $70.82 million | Fiscal year 2015: $50.43 million | Fiscal year 2014: $47.80 million | Fiscal year 2013: $7.08 million | Fiscal year 2012: $662.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: